ESMO - European Society for Medical Oncology

📣 ESMO members: have you downloaded Breast Cancer: Essentials for Clinicians (2nd edition)? Dr Ivana Božović-Spasojević explains why this is important for your practice. 📖 This new book provides dedicated chapters on breast cancer in men, older patients and young women, addressing the specificities of these unique patient populations, while a chapter on survivorship focuses on the management of early and late toxicities during and after treatment. 🔗 https://ow.ly/TGW450Up4Fz #breastcancer #ESMObooks

👉 ESMO Membership value survey: What strengthens the ESMO community? Listening to you. The survey will take under 10 minutes of your time, but the impact of your feedback will be long-lasting. Take the survey today, your opinion matters: 🔗https://ow.ly/5QAn50UgNLI ⏰Survey closes 16 December 2024

📣 Serving as a central hub for the latest research, ethical discussions and technological advancements, the ESMO AI & Digital Oncology Congress fosters learning and collaboration among healthcare and digital health stakeholders. 🤝 A vital platform for experts from various fields to connect and for cancer healthcare practitioners to gain insights into AI and digital health breakthroughs, staying at the forefront of digital transformation in cancer care. Save the date! 📅 12-14.11.2025 #ESMOAI25 🔗https://ow.ly/PXjX50UoiBY

Two studies presented at #ESMOImmuno24 attempted to optimise the use of #immunotherapy in different populations of patients with unresectable stage III non-small cell lung cancer (#NSCLC).  #ESMODailyReporter 📌https://ow.ly/8fyw50UpRjh

Today marks #UniversalHealthCoverage Day, with this year's theme “Health: it’s on the government.” ESMO is pleased to announce that the paper titled "ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update" will be published in #AnnalsOfOncology in January 2025. This study addresses the critical issue of accessibility to #CancerMedicines, focusing on the availability and affordability of safe and effective therapies - essential components for achieving #UniversalHealthCoverage worldwide. Despite advancements in treatment, global disparities persist, resulting in unequal cancer outcomes. ESMO reaffirms its commitment to improving access to effective #CancerInterventions through advocacy efforts at both the European and global levels. #UHCDay #HealthForAll

More than 40% of patients with resectable stage III #melanoma experience disease recurrence within the first few years after initial treatment. The lack of overall survival (OS) benefit with adjuvant immune checkpoint inhibitors (ICIs) has led researchers to explore different approaches. Recent advancements in #MelanomaTreatment, especially with neoadjuvant ICIs, have opened new avenues for improving patient outcomes. Future research will focus on #PersonalisedPlans for individual patients and enhancing our ability to predict both response and toxicities. Read the opinion piece by Prof Dr Christian Blank in the #ESMODailyReporter on the occasion of his keynote lecture at #ESMOImmuno24 📌https://ow.ly/i73A50UpQ1b

Circulating tumour DNA tumour fraction (ctDNA TF) is demonstrating increasing potential in #CancerManagement.Studies presented at #ESMOImmuno24 explore the prognostic and predictive values of ctDNA TF and single-cell RNA sequencing of peripheral blood mononuclear cells. According to Christian Rolfo, MD, PhD, MBA,Dr.hc the future of #LiquidBiopsies in immuno-oncology is clearly bright. 👇Read his commentary in the #ESMODailyReporter https://ow.ly/LCh950UpFo1

Results from the KEYNOTE-867 trial presented at #ESMOImmuno24 show no significant improvement in median event-free survival with pembrolizumab versus placebo given concurrently with stereotactic body radiotherapy and based on the benefit-risk profile the trial was stopped early. Alfredo Addeo in the #ESMODailyReporter article commented that these results, in addition to other recent negative trials, indicate that checkpoint inhibition at the same time as (chemo)radiation does not seem to be a viable therapeutic approach. Further research is needed to understand these treatments' mechanisms and optimal scheduling 📌Read the full article👉 https://ow.ly/WHjW50Up9xl

Three studies presented at #ESMOImmuno24 highlight that #GutMicrobiota not only impacts the response and resistance to #immunotherapy but also plays a significant role in immunotherapy-related toxicities. Discussing the studies for the #ESMODailyReporter, Laurence Zitvogel, explains how these results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration. 👉https://ow.ly/yebB50Up9qn

#ESMOImmuno24: Are we close to personalising immunotherapy? Ton Schumacher is the 2024 ESMO Immuno-Oncology Awardee for his pioneering research into tumour neoantigens and his role as one of the masterminds behind the concept of neoadjuvant immunotherapy. In his interview he looks back at his greatest achievements in the field, and he reflects on the future of cancer immunology and the next frontier for tumour antigen research. 👇Full interview available in the #ESMODailyReporter https://ow.ly/8uwA50Up0B1